Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | APR-246 combination treatments in TP53-mutant R/R NHLs

Meghan Thompson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses an upcoming Phase 1 study (NCT04419389) aiming to evaluate the efficacy and safety of APR-246 in combination with ibrutinib or a venetoclax-based therapy in patients with TP53-mutant relapsed/refractory (R/R) non-Hodgkin lymphomas (NHLs), including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Enrollment for this trial is ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Curio Science